Tabula Rasa Healthcare Inc. (TRHC) PT Raised to $21.00 at Chardan Capital
Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) had its price target hoisted by equities research analysts at Chardan Capital from $19.50 to $21.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target suggests a potential upside of 41.32% from the stock’s previous close.
Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus lowered their price target on shares of Tabula Rasa Healthcare from $19.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 2nd. UBS AG reissued a “buy” rating and issued a $17.00 price target (down previously from $18.00) on shares of Tabula Rasa Healthcare in a report on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $17.50.
Tabula Rasa Healthcare (NASDAQ:TRHC) opened at 14.86 on Tuesday. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $16.85. The stock’s 50 day moving average price is $14.64 and its 200-day moving average price is $14.00. The stock’s market capitalization is $255.86 million.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The business had revenue of $29.70 million for the quarter, compared to the consensus estimate of $27.84 million. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. Analysts expect that Tabula Rasa Healthcare will post $0.41 earnings per share for the current year.
In related news, insider Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $11.94, for a total value of $95,520.00. Following the sale, the insider now directly owns 919,407 shares of the company’s stock, valued at approximately $10,977,719.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glen R. Bressner acquired 7,500 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was bought at an average cost of $11.96 per share, for a total transaction of $89,700.00. Following the completion of the transaction, the director now directly owns 18,256 shares in the company, valued at approximately $218,341.76. The disclosure for this purchase can be found here. Insiders sold a total of 46,759 shares of company stock valued at $634,444 in the last three months. 45.80% of the stock is owned by company insiders.
A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in shares of Tabula Rasa Healthcare by 37.2% in the first quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock valued at $10,544,000 after buying an additional 212,164 shares during the period. Hood River Capital Management LLC boosted its stake in shares of Tabula Rasa Healthcare by 30.1% in the first quarter. Hood River Capital Management LLC now owns 767,501 shares of the company’s stock valued at $10,346,000 after buying an additional 177,774 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Tabula Rasa Healthcare during the third quarter valued at approximately $7,303,000. Cortina Asset Management LLC boosted its stake in shares of Tabula Rasa Healthcare by 16.9% in the fourth quarter. Cortina Asset Management LLC now owns 440,685 shares of the company’s stock valued at $6,601,000 after buying an additional 63,627 shares during the period. Finally, Monashee Investment Management LLC acquired a new stake in shares of Tabula Rasa Healthcare during the third quarter valued at approximately $4,296,000. 24.99% of the stock is currently owned by institutional investors and hedge funds.
About Tabula Rasa Healthcare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.